Effect of desipramine on patients with breathing disorders in RETT syndrome

Abstract

ObjectiveRett Syndrome (RTT) is a severe neurodevelopmental condition with breathing disorders, affecting around one in 10,000 female births. Desipramine, a noradrenaline reuptake inhibitor, reduced the number of apneas in Mecp2‐deficient mice, a model of RTT. We planned a phase 2 trial to test its efficacy and its safety on breathing patterns in 36 girls with RTT.MethodsThe trial was a 6‐month, multicenter, randomized, double‐blind, placebo‐controlled study registered with ClinicalTrials.gov, number NCT00990691. Girls diagnosed according to clinical examination and confirmed by genotyping were randomly assigned in a 1:1:1 ratio to receive 2–3 mg/kg Desipramine per day (high Desipramine), 1–2 mg/kg Desipramine per day (low Desipramine), or a placebo. The primary outcome was the change of apnea hypopnea index (AHI), defined by the number of apnea and hypopnea events per hour, assessed at 6 months from baseline. Intention‐to‐treat analysis was applied.ResultsThe median change in AHI from baseline to 6 months was −31 (IQR: −37 to −11) for the high Desipramine, −17.5 (IQR: −31 to 13) for the low Desipramine, and −13 (IQR:−31 to 0) for the placebo group. We did not find any significant difference in these changes between the groups (P = 0.781). A significant inverse correlation between Desipramine plasma concentration and AHI (r = −0.44; P = 0.0002) was underlined.InterpretationThis first clinical trial of desipramine did not show clinical efficacy. Although required further studies, the significant correlation between Desipramine concentrations and improvement of AHI provided additional and relevant reasons to test the noradrenergic pathway in RTT.

Non‐epileptic paroxysmal events in Rett syndrome: A systematic review of case‐based and observational evidence

“…Breath-holding episodes, reported in at least 35 studies, may be voluntary or involuntary, occur spontaneously or in response to emotional distress, be central or obstructive in nature, and can occur during wakefulness or sleep. 18,35 Respiratory disturbances are frequently associated with autonomic dysfunction, with fluctuations in heart rate and blood pressure. 14 Behaviour manifestations (e.g.…”

A Computational Approach to Identify Novel Protein Targets Uncovers New Potential Mechanisms of Action of Mirtazapine S (+) and R (−) Enantiomers in Rett Syndrome

“…It is a noradrenaline reuptake inhibitor that was able to improve breathing and lifespan in Mecp2-null mice (Roux et al 2007). Unfortunately, the phase II clinical trial was stopped because of cardiovascular side effects (Mancini et al 2018). Although desipramine was not confirmed in patients, the overall results support the possible use of antidepressants in RTT.…”

Key issues in Rett syndrome: emotional, behavioural and autonomic dysregulation (EBAD) - a target for clinical trials

“…No changes in either global severity [ 130 ] or the apnoea index [ 131 ] were noted in comparison to placebo. This was shown in a study of desipramine in 26 patients with RTT whereby no significant differences were found between treatment groups for apnoea-hypopnea index and severity [ 134 ].…”